Opus Genetics, Inc. (NASDAQ: IRD) reported Q3 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.87 million versus the consensus estimate of $2.28 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.